This is a randomized, double blind, placebo-controlled, parallel-arm, multi-center, Phase 2,
proof-of-concept efficacy and safety study in patients with end-stage renal disease requiring
hemodialysis.
The purpose of the study is to determine the efficacy and safety profile of PA101B delivered
via eFlow high efficiency nebulizer in patients with uremic pruritus who are symptomatic
despite using standard treatments.